Literature DB >> 23097680

Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Paul B Larkin1, Paul J Muchowski.   

Abstract

Several genes and proteins of the complement cascade are present at elevated levels in brains of patients with Huntington's disease (HD). The complement cascade is well characterized as an effector arm of the immune system, and in the brain it is important for developmental synapse elimination. We hypothesized that increased levels of complement in HD brains contributes to disease progression, perhaps by contributing to synapse elimination or inflammatory signaling. We tested this hypothesis in the R6/2 mouse model of HD by crossing mice deficient in complement component 3 (C3), a crucial complement protein found at increased levels in HD brains, to R6/2 mice and monitoring behavioral and neuropathological disease progression. We found no alterations in multiple behavioral assays, weight or survival in R6/2 mice lacking C3. We also quantified the expression of several complement cascade genes in R6/2 brains and found that the large scale upregulation of complement genes observed in HD brains is not mirrored in R6/2 brains. These data show that C3 deficiency does not alter disease progression in the R6/2 mouse model of HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23097680      PMCID: PMC3478099          DOI: 10.3233/JHD-2012-120021

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  47 in total

1.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.

Authors:  G J Klapstein; R S Fisher; H Zanjani; C Cepeda; E S Jokel; M F Chesselet; M S Levine
Journal:  J Neurophysiol       Date:  2001-12       Impact factor: 2.714

2.  High-throughput real-time quantitative reverse transcription PCR.

Authors:  Angie L Bookout; Carolyn L Cummins; David J Mangelsdorf; Jean M Pesola; Martha F Kramer
Journal:  Curr Protoc Mol Biol       Date:  2006-02

3.  Activated immune system in patients with Huntington's disease.

Authors:  F Leblhuber; J Walli; K Jellinger; G P Tilz; B Widner; F Laccone; D Fuchs
Journal:  Clin Chem Lab Med       Date:  1998-10       Impact factor: 3.694

4.  Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.

Authors:  S K Singhrao; J W Neal; B P Morgan; P Gasque
Journal:  Exp Neurol       Date:  1999-10       Impact factor: 5.330

5.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

6.  Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.

Authors:  John Labbadia; Helen Cunliffe; Andreas Weiss; Elena Katsyuba; Kirupa Sathasivam; Tamara Seredenina; Ben Woodman; Saliha Moussaoui; Stefan Frentzel; Ruth Luthi-Carter; Paolo Paganetti; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

Review 7.  The complement system in liver diseases.

Authors:  Xuebin Qin; Bin Gao
Journal:  Cell Mol Immunol       Date:  2006-10       Impact factor: 11.530

8.  Complement: a novel factor in basal and ischemia-induced neurogenesis.

Authors:  Yalda Rahpeymai; Max Albert Hietala; Ulrika Wilhelmsson; Andrew Fotheringham; Ioan Davies; Ann-Katrin Nilsson; Jörg Zwirner; Rick A Wetsel; Craig Gerard; Milos Pekny; Marcela Pekna
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

9.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Authors:  Liliana Menalled; Bassem F El-Khodor; Monica Patry; Mayte Suárez-Fariñas; Samantha J Orenstein; Benjamin Zahasky; Christina Leahy; Vanessa Wheeler; X William Yang; Marcy MacDonald; A Jennifer Morton; Gill Bates; Janet Leeds; Larry Park; David Howland; Ethan Signer; Allan Tobin; Daniela Brunner
Journal:  Neurobiol Dis       Date:  2009-05-21       Impact factor: 5.996

10.  C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse.

Authors:  Scott E Wenderfer; Hongyu Wang; Baozhen Ke; Rick A Wetsel; Michael C Braun
Journal:  Mol Immunol       Date:  2009-01-23       Impact factor: 4.407

View more
  9 in total

Review 1.  The choreography of neuroinflammation in Huntington's disease.

Authors:  Andrea Crotti; Christopher K Glass
Journal:  Trends Immunol       Date:  2015-05-20       Impact factor: 16.687

2.  αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.

Authors:  Ana Osório Oliveira; Alexander Osmand; Tiago Fleming Outeiro; Paul Joseph Muchowski; Steven Finkbeiner
Journal:  Hum Mol Genet       Date:  2016-02-26       Impact factor: 6.150

Review 3.  The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration.

Authors:  Ying Chen; John Man Tak Chu; Raymond Chuen Chung Chang; Gordon Tin Chun Wong
Journal:  Biomolecules       Date:  2022-02-21

Review 4.  Aberrant Complement System Activation in Neurological Disorders.

Authors:  Karolina Ziabska; Malgorzata Ziemka-Nalecz; Paulina Pawelec; Joanna Sypecka; Teresa Zalewska
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model.

Authors:  Daniela Diamanti; Elisa Mori; Danny Incarnato; Federico Malusa; Costanza Fondelli; Letizia Magnoni; Giuseppe Pollio
Journal:  Biomark Res       Date:  2013-10-23

Review 6.  Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.

Authors:  Sarah M Carpanini; Megan Torvell; Bryan Paul Morgan
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

Review 7.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

Review 8.  Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies.

Authors:  Natalia P Rocha; Fabiola M Ribeiro; Erin Furr-Stimming; Antonio L Teixeira
Journal:  Mediators Inflamm       Date:  2016-08-08       Impact factor: 4.711

Review 9.  Complement proteins in unexpected places: why we should be excited, not concerned!

Authors:  Berhane Ghebrehiwet
Journal:  F1000Res       Date:  2020-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.